MDX2003 targets CD19 and CD20 on B cells and CD3 and CD28 on T cells, enhancing antitumor activity and reducing antigen loss. The therapy's design limits cytokine release syndrome, showing improved ...
– Phase 1 healthy volunteer study of half-life extended anti-TL1A antibody XmAb942 to dose first subject in Q4 2024, with data anticipated in the first half of 2025 – – XmAb® T-cell engagers ...
Merck & Co. Inc. is acquiring Curon Biopharmaceutical Ltd.’s bispecific antibody CN-201 that targets CD3 and CD19 for B-cell associated diseases, for up to $1.3 billion. Under the terms of the deal, ...
Ibrahim Aldoss, MD, discusses the potential of AZD0486 for treating relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) and outlines the SYRUS study objectives. AZD0486 is a novel IgG ...
Title: ATG-201, a Novel Steric Hindrance-based Masking CD19xCD3 T-cell Engager (TCE) for the Treatment of B Cell-related Autoimmune Diseases Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) ...
Antibody drugs that go after two targets have already made their mark in blood cancers, but the field is working to improve on the safety and efficacy of this approach. Merck is getting a contender ...
Blinatumomab is a bispecific CD19-directed CD3 T-cell engager. The Food and Drug Administration (FDA) has approved Blincyto ® (blinatumomab) for the treatment of adult and pediatric patients 1 month ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results